ctDNA-Based MRD Testing

Precise MRD Detection. Confident Decisions During Treatment and Surveillance.

LymphoVista delivers ctDNA results at the milestones that shape your clinical decisions: during treatment, after treatment, and during follow-up. Clinically validated for lymphoma.

Validated In-House IVD Test

Presented at ASH 2024 · EHA 2024

Request a Collection Kit Speak with a Specialist
Test Variants

Two Specialized Panels

LymphoVista offers disease-specific ctDNA assays optimized for B-cell lymphomas and Hodgkin lymphoma respectively. Select a variant to view its specifications and clinical evidence.

LymphoVista

For B-Cell Lymphomas

(D)LBCL Follicular Lymphoma Mantle Cell Lymphoma Marginal Zone Lymphoma Burkitt Lymphoma CNS Lymphomas
Sensitivity 93.86%
Specificity 99.999%
Limit of Detection (LoD) for MRD 6.69 × 10⁻⁶

Clinical validation · relapsed/refractory DLBCL

18-month OS

77% MRD-negative
vs
33% MRD-positive
HR 4.61 p < 0.0001

18-month PFS

51% MRD-negative
vs
5% MRD-positive
HR 4.32 p < 0.0001

HR (Hazard Ratio): the relative risk of the event between groups. Higher means greater risk for the MRD-positive group. p: the probability this difference occurred by chance. The smaller, the stronger the evidence.

See published survival data ↓
Clinical Validation

6.69 × 10⁻⁶

Limit of Detection (LoD)

For lymphoma MRD

>99%

Variant Detection Specificity

Genotyping / variant detection

10–15

Business Days

Turnaround time for an interpreted report

97%

PFS After 4 Years

MRD-negativity (HD21 study; Heger et al.)

Internal validation. Data on file.

Clinical Value

Four Decisions Enabled

MRD Detection
Detect minimal residual disease earlier than imaging often months before clinical relapse.
Therapy Monitoring
Monitor treatment response continuously with ctDNA and adjust protocols based on real-time molecular data.
Early Relapse Detection
Identify relapses months before radiological appearance act while options are still broad.
Risk Stratification
Stratify relapse risk accurately to guide personalized treatment decisions.
Published Data

Clinical Evidence

rrLBCL (Relapsed/Refractory Large B-Cell Lymphoma)

Kaplan-Meier overall survival curve by MRD status for B-cell lymphoma

Schleifenbaum et al., EHA 2024

Want all three indications in one document? Download the LymphoVista Service Profile (PDF).

How It Works

Three steps. Precise results. Confident decisions.

01

Characterize

Draw 20 ml of peripheral blood to build a patient-specific mutation profile. No specialized lab equipment or added training required.

02

Monitor

Serial ctDNA testing at each treatment milestone tracks disease burden, often months before imaging can detect a relapse.

03

Decide

Our results let you make confident decisions about the next steps in treatment or follow-up care.

Dr. Sven Borchmann, Founder & Managing Director of LIQOMICS
From the Founder

Built by a physician, for patients and colleagues

"Lymphoma patients shouldn't have to wait for the next scan to know if their therapy is working. ctDNA gives us that signal in real time. That's what we're building at LIQOMICS."
Sven Borchmann, MD, PhD Founder & Managing Director, LIQOMICS
Get Started

Precise MRD in lymphoma. Confident decisions.

Request a collection kit or speak directly with a LIQOMICS specialist to discuss your case.

Speak with a Specialist Request a Collection Kit